Stocklytics Platform
Asset logo for symbol DVAX
Dynavax Technologies
DVAX66
$12.94arrow_drop_up0.70%$0.08
Asset logo for symbol DVAX
DVAX66

$12.94

arrow_drop_up0.70%
Key Stats
Open$12.88
Prev. Close$12.85
EPS0.15
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range12.88
12.94
52 Week Range9.74
15.15
Ratios
EPS0.15
Fundamentals
Payout Ratio-
Industry average yield2.72%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

DVAX-
US Healthcare Sector-
US Market-
check_circle

DVAX / Market

DVAX exceeded the US Market which returned -0.72% over the last twenty four hours.
warning

DVAX / Healthcare Sector

DVAX lose to the US Healthcare sector which returned 2.70% over the last twenty four hours.

Dynavax Technologies (DVAX) Statistics

Dynavax Technologies Corp (DVAX) is a biopharmaceutical company dedicated to developing and commercializing innovative vaccines to prevent and treat infectious diseases. As of the latest statistics, DVAX stock has a market capitalization of $1.83 billion and a 52-week high of $27.90. The stock has shown strong performance, outperforming the sector by an impressive margin. In terms of valuation metrics, DVAX has a price-to-earnings ratio of -4.33, indicating that the company is currently operating at a loss.
The fundamentals of Dynavax Technologies Corp are promising. The company has a solid revenue per share of $12.17, demonstrating its ability to generate income. Additionally, its enterprise to EBITDA ratio stands at -5.10, indicating a strong cash flow and financial stability. DVAX also boasts a healthy profit margin of -481.11%, showing significant potential for profitability in the future. Notably, the company has managed to keep its total debt at a manageable level of $50 million, ensuring a sustainable financial position. Lastly, Dynavax Technologies Corp has achieved a gross profit of $1.25 billion, reflecting its ability to generate substantial revenue.
add Dynavax Technologies to watchlist

Keep an eye on Dynavax Technologies

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Dynavax Technologies (DVAX) stock's performance compared to its sector and the market over the past year?

Over the past year, Dynavax Technologies (DVAX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 27.36%, Dynavax Technologies has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 60.25%, it has fallen short of the market average. This comparison highlights Dynavax Technologies's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Dynavax Technologies (DVAX) stock?

The PE (Price to Earnings) ratio of Dynavax Technologies (DVAX) is currently 86.27. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help

What is the EPS of Dynavax Technologies (DVAX) stock?

The Earnings Per Share (EPS) for Dynavax Technologies (DVAX), calculated on a diluted basis, is $0.15. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Dynavax Technologies (DVAX) stock?

The operating margin for Dynavax Technologies (DVAX) is 15.24%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Dynavax Technologies (DVAX) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Dynavax Technologies (DVAX) is $20.98M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Dynavax Technologies (DVAX) have?

Dynavax Technologies (DVAX) has a total debt of $254.59M. The net debt, which accounts for cash and cash equivalents against the total debt, is $130.84M.

Take Your Investments to a Whole New Level